Driptane® [Oxybutynin]
Fournier
1514 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Antispasmodic, myotropic. Driptanee relaxes the detrusor (bladder contraction muscle). It has a direct antispasmodic myotropic and m-anticholinergic action. Increases the capacity of the bladder, reduces the frequency of detrusor contractions, restrains the urge to urinate.
Indications
- urinary incontinence associated with instability of bladder function, impaired or as a result of neurogenic disorders (hyperreflex detrusor), for example, in case of widespread sclerosis or spina bifida, or idiopathic dysfunction of the detrusor (motor incontinence);
- Nocturnal enuresis in children over 5 years old.
Composition
1 tablet contains:
active substance: oxybutynin hydrochloride 5 mg
Excipients: microcrystalline cellulose, calcium stearate, anhydrous lactose.
No customer reviews for the moment.
Dosage and Administration
Driptanee is taken orally. Adults - 5 mg 2-3 times a day, children and elderly patients - 5 mg 2 times a day.
Adverse reactions
Nausea, constipation, diarrhea, abdominal discomfort, urinary retention, drowsiness or insomnia, general weakness, headache, dizziness, arrhythmia, blurred vision (mydriasis, accommodation paralysis), increased intraocular pressure, decreased sweating, dry mouth, impotence, allergic reactions.
Contraindications
- hypersensitivity to Driptanee components;
- angle-closure glaucoma;
- obstruction of the gastrointestinal tract, intestinal atony, expansion of the colon, ulcerative colitis;
- myasthenia gravis;
- obstructive uropathy;
- bleeding;
- breastfeeding period;
- children's age up to 5 years.
Special instructions
Caution is needed in violation of the functions of the kidneys and liver, hyperthyroidism, coronary artery disease, heart failure, arrhythmias, hypertension, prostate adenoma, hernia of the esophageal orifice of the diaphragm.
Overdosage
Symptoms: CNS agitation (anxiety, tremor, increased nervous irritability, convulsions, delirium, hallucinations), fever, nausea, vomiting, tachycardia, lowering blood pressure, respiratory failure, paralysis, coma.
Treatment: one should maintain breathing, induce vomiting or carry out gastric lavage, administer activated charcoal and saline laxative. For regression of symptoms of anticholinergic intoxication, cholinesterase blockers (physostigmine) are used. When expressed anxiety or agitation - IV the introduction of 10 mg of diazepam. With tachycardia - propranolol (w / w).
- Fibrinolytische Behandlung von akuten und subakuten Thrombosen der tiefen Venen des Schultergürtels
- Treatment of overactive bladder with modified intravesical oxybutynin chloride
- Equilibrium studies on enantioselective extraction of oxybutynin enantiomers by hydrophilic β-cyclodextrin derivatives
- Metabolism of oxybutynin: Establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparations using deuterium substitution and gas chromatographic mass spectrometric analysis
- A Practical Synthesis of (S)-Oxybutynin.
- Catalytic Asymmetric Synthesis of (S)-Oxybutynin and a Versatile Intermediate for Antimuscarinic Agents.
- A semiparametric deconvolution model to establish in vivo–in vitro correlation applied to OROS oxybutynin
- Treatment of micturitional disorders in the Shy-Drager syndrome with oxybutynin chloride and self intermittent catheterization
- Effect of oxybutynin on reflex micturition in the decerebrate dog as determined by urodynamic evaluation
- Relaxation of intestinal bladders by intravesical oxybutynin chloride
- Epistaxis as a side effect of oxybutynin in children: Report of two cases
- Intravesical oxybutynin in patients with posterior rhizotomies and sacral anterior root stimulators
- Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: New insights into the working mechanism of antimuscarinics
- The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity
- High-performance liquid chromatographic preparation of oxybutynin enantiomers on a chiral stationary phase
- Reproductive toxicity studies with oxybutynin hydrochloride
- New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin
- Oxybutynin permeation in skin: The influence of drug and solvent activity
- Design, synthesis and activity of novel derivatives of Oxybutynin and Tolterodine
- Patient satisfaction with transdermal oxybutynin: Interim results from the matrix study
- LBOVI-A-1Does prior treatment for overactive bladder affect quality of life outcomes with transdermal oxybutynin? Results from the MATRIX study
- Adsorptive stripping voltammetric behavior and determination of anticholinergic agent oxybutynin chloride on a mercury electrode
- The investigation of the interaction between oxybutynin hydrochloride and bovine serum albumin by spectroscopic methods
- Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations
- Catalytic asymmetric synthesis of (S)-oxybutynin and a versatile intermediate for antimuscarinic agents
8 other products in the same category:
arrow_upward